Answers are grounded in this paper and cite their sources.
RATIONALE: This is an update of a previously published review. Women with infertility may use adjunctive therapies to improve reproductive outcomes. Myo-inositol and D-chiro-inositol are dietary supplements widely available and commonly used by women with polycystic ovary syndrome (PCOS; renamed polyendocrine metabolic ovarian syndrome (PMOS) in May 2026). The use of inositol for women with PCOS and infertility is based on proposed effects on insulin sensitivity and ovarian function. In clinical practice, myo-inositol is frequently prescribed for women with PCOS undergoing ovulation induction/intrauterine insemination or before in vitro fertilisation (IVF). However, the quality and certainty of the evidence supporting this practice remains unclear. This review aimed to assess the benefits and harms of inositol (including myo-inositol and D-chiro-inositol) in women with PCOS experiencing infertility. OBJECTIVES: To evaluate the benefits and harms of inositol oral supplementation for reproductive outcomes among women with polycystic ovary syndrome experiencing infertility. SEARCH METHODS: We searched CENTRAL (which includes trial registries), the Cochrane Gynaecology and Fertility Group Specialised Register, MEDLINE, Embase, PsycINFO, AMED, and Epistemonikos to 10 November 2025. We also checked reference lists and contacted experts in the field for any additional trials. ELIGIBILITY CRITERIA: We included randomised controlled trials (RCTs) that compared any type, dose, or combination of oral inositol versus placebo, no treatment, or another active intervention in women with PCOS and infertility. Trials that compared different types of inositol were also eligible. OUTCOMES: Our critical outcomes were live birth and any adverse event (including miscarriage, multiple pregnancy, and ovarian hyperstimulation syndrome (OHSS)), as reported by trial investigators. Our important outcomes were clinical pregnancy and gestational diabetes. RISK OF BIAS: We assessed risk of bias using the Cochrane RoB 1 tool. SYNTHESIS METHODS: Two review authors independently selected eligible studies, extracted data, and assessed risk of bias. We pooled studies using a fixed-effect model, and calculated odds ratios (ORs) with 95% confidence intervals (CIs). We assessed the overall certainty of evidence by applying GRADE. The primary analyses of all review outcomes were restricted to studies at low risk of selection bias. We also conducted sensitivity analyses including all studies. INCLUDED STUDIES: This review update included 21 studies involving 1634 women with PCOS and infertility who were trying to become pregnant. Sixteen studies and 1481 participants are new to this review. Studies took place in Iran, India, Italy, Albania, Germany, and Vietnam. All women included in these studies were receiving usual preconception care. All studies that met our eligibility criteria and had data for the outcomes of interest investigated myo-inositol. RESULTS: We considered the certainty of the evidence to be low and very low, downgraded mainly due to indirectness and imprecision. The primary analysis included five studies. Myo-inositol compared to placebo or no treatment in women with polycystic ovary syndrome undergoing ovulation induction/intrauterine insemination One study with 120 women evaluated this comparison. As the certainty of the evidence was very low for all outcomes of interest, we are unsure whether myo-inositol, compared with no treatment, has an effect on live birth (OR 3.45, 95% CI 1.63 to 7.32), miscarriage (OR 1.27, 95% CI 0.32 to 4.99), multiple pregnancy (OR 5.36, 95% CI 0.61 to 47.36), OHSS (OR 11.99, 95% CI 0.65 to 221.86), clinical pregnancy (OR 3.45, 95% CI 1.63 to 7.32), or gestational diabetes (OR 1.73, 95% CI 0.39 to 7.58). Myo-inositol compared to placebo or no treatment in women with polycystic ovary syndrome undergoing in vitro fertilisation We are uncertain whether myo-inositol, compared with no treatment, has an effect on live birth (OR 2.42, 95% CI 0.75 to 7.83; 2 studies, 84 women; very low-certainty evidence) and miscarriage (OR 2.09, 95% CI 0.18 to 24.61; 2 studies, 84 women; very low-certainty evidence). The analysis for multiple pregnancy included one trial with no events in either arm (34 women; very low-certainty evidence). Myo-inositol may increase clinical pregnancy rates slightly compared with no treatment (OR 2.34, 95% CI 1.07 to 5.11; 3 studies, 164 women; low-certainty evidence). No studies reported OHSS or gestational diabetes. Myo-inositol compared to another insulin-sensitising agent (metformin) in women with polycystic ovary syndrome undergoing in vitro fertilisation One study with 102 women evaluated this comparison. As the certainty of the evidence was very low for all reported outcomes of interest, we are unsure whether myo-inositol, compared with metformin, has an effect on live birth (OR 3.03, 95% CI 1.12 to 8.17), miscarriage (OR 2.17, 95% CI 0.38 to 12.43), OHSS (OR 0.37, 95% CI 0.12 to 1.14), or clinical pregnancy (OR 3.19, 95% CI 1.28 to 7.95). The study did not report multiple pregnancy or gestational diabetes. AUTHORS' CONCLUSIONS: In light of the very low-certainty evidence available from one study, we are unsure whether myo-inositol, compared with no treatment, has an effect on live birth, miscarriage, multiple pregnancy, OHSS, clinical pregnancy, or gestational diabetes in women with PCOS and infertility undergoing ovulation induction/intrauterine insemination. In studies comparing myo-inositol with no treatment in women undergoing IVF, the certainty of the evidence was very low for live birth, miscarriage, and multiple pregnancy. Low-certainty evidence from three of these studies indicated there may be a slight increase in clinical pregnancy rates for women taking myo-inositol compared with those receiving no treatment. In light of the very low-certainty evidence available from one study, we are unsure whether myo-inositol, compared with metformin, has an effect on live birth, miscarriage, OHSS, or clinical pregnancy in women undergoing IVF. FUNDING: This Cochrane review had no dedicated funding. REGISTRATION: Protocol (2016) available at https://doi.org/10.1002/14651858.CD012378. Previous review (2018) available at https://doi.org/10.1002/14651858.CD012378.pub2.
No takes yet. Share an insight, caveat, or question.
Vercoe et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: